Results 171 to 180 of about 22,351 (243)

Peroxiredoxin 6 Alone or in Combination with Fingolimod Ameliorates EAE. [PDF]

Curr Neuropharmacol
Lunin SM, Novoselova EG, Glushkova OV, Parfenyuk SB, Kuzekova AA, Novoselova TV, Sharapov MG, Mubarakshina EK, Goncharov RG, Khrenov MO.   +9 more
europepmc   +1 more source

International Expert Opinion on Optimal Switching to Cladribine Tablets from Other High-Efficacy Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: Opportunities and Challenges. [PDF]

Neurol Ther
Chan A, Alroughani R, Calabrese M, Havrdová EK, Obeidat AZ, Schmierer K, Andersson M, Bek L, Savarin C, Korich J, Bonsignore L, de Seze J.   +11 more
europepmc   +1 more source

External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis. [PDF]

Cost Eff Resour Alloc
Campello CRS, da Costa MGS, Pinto M.
europepmc   +1 more source

Blocking Sphingosine 1-phosphate Metabolism With Fingolimod Prevents the Progression of Vascular Smooth Muscle Cells Calcification in Chronic Kidney Disease. [PDF]

J Cell Physiol
Skafi N, Pelletier S, Soulage CO, Nahle S, Da Cruz BO, Othmani R, Briolay A, Reibel S, Vitale N, Hamade E, Badran B, Magne D, Buchet R, Stockler-Pinto MB, Fouque D, Mebarek S, Brizuela L.   +16 more
europepmc   +1 more source

Effects of disease-modifying drugs on serum neurofilament light chain, chitinase-3-like-1 protein levels, and selected plasmacytoid dendritic cell biomarkers in relapsing-remitting multiple sclerosis. [PDF]

Afr J Lab Med
Kamal DT, Sayed SK, Rageh TA, Rashad B, Badawy ER.   +4 more
europepmc   +1 more source

Efficacy and safety of disease-modifying oral drugs in treatment of relapsing-remitting multiple sclerosis: systematic review and network meta-analysis. [PDF]

Front Immunol
Zhao Y, Chen B, Zhao X, Yang R, He W, Li D, Sun Q, Zhang J, Liu X.   +8 more
europepmc   +1 more source

Pediatric-Onset Multiple Sclerosis at Age 10 Following Nephrotic Syndrome: Early Recognition and Successful Treatment With Fingolimod. [PDF]

Cureus
Mezdaoui I, Mouaddine K, Nahi C, Chkirate B.   +3 more
europepmc   +1 more source

Editorial: Innovative approaches to preventing and treating biofilm-associated infections. [PDF]

Front Cell Infect Microbiol
Arya R, Joshi B.
europepmc   +1 more source

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study. [PDF]

Front Neurol
Huygens S, Versteegh M, Berg-Hansen P, Bjelland SH, Holmøy T, Torkildsen Ø.   +5 more
europepmc   +1 more source

Case Report: Hemorrhagic Vasculitis in a Patient With Multiple Sclerosis Receiving Fingolimod. [PDF]

Clin Case Rep
Zeynali Esfahani F, Payere M, Karimikhoshnoudian B, Baghaei M, Nahayati M.   +4 more
europepmc   +1 more source